Study identifier:D8221R00002
ClinicalTrials.gov identifier:NCT06205498
EudraCT identifier:N/A
CTIS identifier:N/A
Acalabrutinib Real world Italian obSErvational secondary data collection study of acalabrutinib in the treatment of patients with chronic lymphocytic leukemia.
Chronic Lymphocytic Leukemia
Phase 4
No
acalabrutinib
All
190
Observational
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
Yghea
No locations available
Arms | Assigned Interventions |
---|